Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q4 CY2025 results , with sales up 17% year on year to $874.6 ...

As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened regulatory scrutiny, the role of the top pharmaceutical API manufacturer has taken on ...

AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, Bernstein lifted the price target on BioMarin Pharmaceutical Inc.

The third quarter was a pivotal period for both the biotech and pharmaceutical sectors, with regulatory developments and an increase in business deals shaping the landscape for the industries. Public ...

By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology ...

The Parenteral Drug Association(PDA) will be celebrating 80 years of service to our members and the wider industry at PDA Week 2026. Since 1946 PDA has worked tirelessly to advance pharma ...

When MEI Pharma announced it was considering its “strategic alternatives” in the wake of a failed merger last year, the options seemed pretty mundane. But, rather than winding down the company as the ...

Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. | Gilead penned a potential ...

In this article, we will look at the 12 Cheap Biotech Stocks to Buy Now.